Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betahistin (ausschl. Wirkstärke 6 mg und 12 mg) f. d. Z. 01.10.2026 - 30.09.2028 (zzgl. V.-Option 1x12 Mon)

TENDER DESCRIPTION

DAK-Gesundheit assumes that this procedure does not fall under the scope of cartel procurement law due to the absence of a selection decision and thus the non-discriminatory access opportunity for all pharmaceutical companies. It will end automatically regardless upon the entry into force of the exclusive contract for the active substance Betahistine (exclusively strengths 6 mg and 12 mg), ATC N07CA01, following a formal procurement procedure under the regulations of Part 4 of the GWB with one or more contracting partners. To do justice to the diversity of potential contracting partners within the approval model, every pharmaceutical company is enabled to conclude a framework contract at any time and under the same conditions during the contract term. The necessary contract documents are available for download via the online portal www.dtvp.de/center at the link specified under 5.1.11. Prerequisites for concluding or later joining the contracts, which come into effect for the first time on 01.10.2026, are the complete and timely submission of the following documents (available for download at the link specified under 5.1.11) to the following department at DAK-Gesundheit: 1.…

TENDER BRIEF

TENDER DOCUMENTS